- prevention of neonatal infections (including prematures with low birth weight particularly vulnerable to infections) allowing to maintain or restore normal bacterial flora – reduction the risk of newborn infections leading to sepsis;
- prevention and treatment of chronic inflammatory bowel diseases;
- dietary supplement used in the prevention and/or treatment of bacterial and viral infections;
- preparation supporting the treatment of patients on antibiotic therapy, cancer patients and those suffering from chronic intestinal inflammation.
- distinct stimulatory effect on growth of the probiotic Lactobacillus bacteria;
- the possibility to saturate the complex exclusively with particularly advantageous and safe manganese on the third oxidation state;
- absence of ferric ions indispensable for growth of pathogenic bacteria and preserved ability of the complex to uptake ferric ions after release of manganese in the gastrointestinal tract;
- high absorption of manganese and its gradual release in the human body, resulting in increased safety.
The invention in addition to stimulatory effect on growth of probiotic bacteria colonies retains all beneficial features of commercially available preparations of lactoferrin.
The invention is subject to patent application covering the formulation, method of its manufacture and use. Further research is conducted at the Faculty of Chemistry, JagiellonianUniversity and the Faculty of Pharmacy, JagiellonianUniversityMedicalCollege.
Currently the Centre for Technology Transfer CITTRU is looking for entities interested in licensing and commercial application of described invention. Cooperation with partners interested in joint R&D projects in scientific topic related to the invention is also desirable.